New Delhi: India’s top vaccine advisory panel failed to reach a consensus on both the booster dose and the vaccination of children amid the rise in Omicron cases on Monday.
The National Technical Advisory Group on Immunization (NTAGI) discussed at length whether to allow an additional dose for immunocompromised people or those more at risk from the deadly virus.
However, no final recommendation was made, say reports. The group is also likely to formulate a policy on inoculating children — the only group left out of vaccinations so far.
“The meeting put light on COVID-19 vaccination, additional doses and vaccination for children but due to no consensus over the issues final recommendation couldn’t be made,” sources were quoted as saying by news agency ANI.
According to the panel members, a decision on boosters was not on the meeting’s agenda. The panel drew a distinction between a booster dose and an additional jab. If two doses fail to build immunity, an additional dose is given.
The government has, for now, held off on boosters. Health Minister Mansukh Mandaviya told parliament recently that NTAGI and the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) were deliberating and considering scientific evidence related to this aspect.
ALSO READ: Over 100 Foreign Returnees Go Untraceable Near Mumbai Amid Omicron Scare
Stay ahead with Odisha Bytes Breaking News - your ultimate source for the fastest, most… Read More
Bhubaneswar: The ‘BRICS Youth Council Entrepreneurship Pre-Consultation meet was organised by KIIT-TBI on Tuesday, bringing… Read More
Canada: Several gunshots were reportedly fired outside singer Prem Dhillon's residence in Canada apparently by… Read More
New Delhi: After teaming up with Akshay Kumar for horror-comedy ‘Bhooth Bangla,’ Tabu has hinted… Read More
Bhubaneswar: A 37-year-old married man was arrested in Bhubaneswar on Tuesday for allegedly deceiving multiple… Read More
Bhubaneswar: The BSNL, one of India's leading Telecom operators, has announced to discontinue three of… Read More
This website uses cookies.